Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CAO Sells $15,818.78 in Stock

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) CAO Carrie Liao sold 2,347 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $15,818.78. Following the completion of the sale, the chief accounting officer now owns 144,923 shares in the company, valued at $976,781.02. The trade was a 1.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Carrie Liao also recently made the following trade(s):

• On Thursday, December 26th, Carrie Liao sold 2,273 shares of Mind Medicine (MindMed) stock. The stock was sold at an average price of $7.43, for a total value of $16,888.39.

Mind Medicine (MindMed) Trading Down 3.7 %

Shares of Mind Medicine (MindMed) stock opened at $6.19 on Friday. Mind Medicine has a twelve month low of $5.03 and a twelve month high of $12.22. The firm’s 50-day moving average price is $7.26 and its 200 day moving average price is $6.95. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $466.53 million, a PE ratio of -2.74 and a beta of 2.57.

Mind Medicine (MindMed) (NASDAQ:MNMD) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08). During the same period in the previous year, the business earned ($0.59) earnings per share. On average, sell-side analysts predict that Mind Medicine will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of large investors have recently modified their holdings of the business. Marshall Wace LLP lifted its stake in shares of Mind Medicine (MindMed) by 9.3% in the fourth quarter. Marshall Wace LLP now owns 2,501,391 shares of the company’s stock worth $17,410,000 after buying an additional 213,526 shares in the last quarter. State Street Corp lifted its stake in Mind Medicine (MindMed) by 0.5% in the 3rd quarter. State Street Corp now owns 1,814,829 shares of the company’s stock worth $10,326,000 after purchasing an additional 9,782 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Mind Medicine (MindMed) by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,723,088 shares of the company’s stock worth $11,996,000 after purchasing an additional 45,386 shares during the last quarter. AWM Investment Company Inc. grew its position in shares of Mind Medicine (MindMed) by 39.9% in the fourth quarter. AWM Investment Company Inc. now owns 1,193,162 shares of the company’s stock valued at $8,304,000 after purchasing an additional 340,162 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in shares of Mind Medicine (MindMed) by 0.3% in the fourth quarter. Woodline Partners LP now owns 1,005,198 shares of the company’s stock valued at $6,996,000 after purchasing an additional 2,654 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on MNMD. Evercore ISI initiated coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Chardan Capital initiated coverage on shares of Mind Medicine (MindMed) in a report on Friday, December 20th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Robert W. Baird decreased their price objective on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Ten equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of “Buy” and an average target price of $25.11.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.